CAS Number: 920509-32-6

Stage: Commercial

End Use: Resmetirom

Resmetirom is a thyroid hormone receptor-beta agonist used to treat noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis in adults. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). This is a monumental advancement in the treatment of Non-Alcoholic Steatohepatitis (NASH), a condition lacking specific pharmacological interventions since its identication in 1980. Resmetirom,  has emerged as a promising therapeutic option for NASH as  Clinical trials have demonstrated its efficacy in resolving NASH and ameliorating fibrosis, offering hope to patients and healthcare providers alike.

Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. The approval of Resmetirom marks a watershed moment 44 years into the fight against NASH, o­ffering hope to millions of patients worldwide.

1. We are Completely backward integrated offering all the intermediates of this molecule ( can portray as an end-to-end soln provider).

2. With our FDA-Approved Site in compliance with WHO-GMP, We ensure to match quality as per industry standards & strong regulatory support.

3. One of the early movers in the market – producing all the intermediates in-house & ensuring no reliability on imports for KSMs

4. Tech Pack is available – For more details contact us: rahilmehta@royalpharma.in